According to the latest report by IMARC Group, titled “Europe Hospital Acquired Disease Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the Europe hospital acquired disease testing market exhibited robust growth during 2015-2020. Looking forward, IMARC Group expects the market to continue its robust growth during 2021-2026.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request Free Report Sample: https://www.imarcgroup.com/europe-hospital-acquired-disease-testing-market/requestsample
Hospital-acquired diseases (HADs) or nosocomial diseases are illnesses caused by exposure to bacterial, viral, and fungal pathogens during hospital visits. Most people contract HAIs in intensive care units (ICU) and the emergency rooms (ERs). The commonly acquired infections include surgical site infections (SSI), catheter-association urinary tract infections (CAUTI), ventilator-associated pneumonia (VAP), and hospital-acquired pneumonia (HAP). A lack of proper hygiene in the hospital is one of the prime reasons behind hospital-acquired diseases.
Checkout- https://www.imarcgroup.com/checkout?id=2990&method=1
The development of innovative diagnostic technologies and instruments, such as mass spectrometry, near-infrared spectrometry, and flow cytometry, and the rising awareness of HAIs among the patients represent some of the key factors providing driving the market growth. The increasing prevalence of HADs across the region is acting as another major growth-inducing factor. Other factors, such as extensive research and development (R&D) activities, are creating a positive outlook for the market in Europe.
Europe Hospital Acquired Disease Testing Market 2021-2026 Competitive Analysis and Segmentation:
Competitive Landscape With Key Players:
The competitive landscape of the europe hospital acquired disease testing market has been studied in the report with the detailed profiles of the key players operating in the market.
Key Market Segmentation:
The report has segmented the europe hospital acquired disease testing market on the basis of indication and country.
Breakup by Indication:
- UTI (Urinary Tract Infection)
- SSI (Surgical Site Infection)
- Pneumonia
- Bloodstream Infections
- MRSA (Methicillin-Resistant Staphylococcus Aureus)
- Others
Breakup by Country:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/europe-hospital-acquired-disease-testing-market
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021-2026)
- Industry Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800